Bivalent Vaccine Effectiveness Against Type-Specific HPV Positivity: Evidence for Cross-Protection Against Oncogenic Types Among Dutch STI Clinic Visitors

نویسندگان

  • Petra J Woestenberg
  • Audrey J King
  • Birgit H B van Benthem
  • Robine Donken
  • Suzan Leussink
  • Fiona R M van der Klis
  • Hester E de Melker
  • Marianne A B van der Sande
  • Christian J P A Hoebe
  • Johannes A Bogaards
  • D Adema
  • R Buist-Arkema
  • A Beerens
  • D Luijt
  • S Meijer
  • J Schirm
  • M Peeters
  • J Rossen
  • H Verbakel
  • P van Esch
  • J Verweij
  • A van der Eijk
  • R Huisman
  • C Kerkhof
  • H Korff
  • M Schutten
  • J Velzing
  • F Verduyn-Lunel
  • S Lakbiach
  • P van Rosmalen
  • R Schuurman
  • D Abma
  • K Adams
  • S Bruisten
  • I Linde
  • P Oostvogel
  • C Touwen
  • W Vermeulen
  • A Brink
  • J Nelissen
  • P Wolffs
  • N Duijvendijk
  • P Schneeberger
  • M Dinnissen van Poppel
  • W Melchers
  • Y Poort
  • M Hooghiemstra
  • H Huisman
  • J Weel
  • F Bosma
  • F Geeraedts
  • I Polman
  • P van Goor
  • M Wolfhagen
  • C de Mooij
  • E van Koolwijk
  • M Peters
  • C Swanink
  • R Tiemessen
  • T van Zwet
  • J Janssen
  • M Pelsers
  • W de Waal
  • G Aalfs
  • J Kiewiet
  • P Sanders
  • H van Buel-Bruins
  • C van Bokhoven-Rombouts
  • P Cornelissen
  • M Kersten
  • C van Ruitenbeek
  • I Molenaar
  • E Doorn
  • L Masthoff
  • E Pannekoek
  • V Sigurdsson
  • M Bugter
  • H Götz
  • M Illidge-Onder de Linden
  • M Mattijssen
  • J Stam
  • E Swaders
  • F de Groot
  • F Postma
  • E Brouwers
  • A Niekamp
  • M Smit
  • A Botraby
  • D Bukasa
  • C de Haan
  • P Hut-van Vliet
  • T Taconis
  • M de Graas
  • I Hondelink
  • C Kampman
  • A Gelissen-Hansen
  • I de Koning
  • H van Kruchten
  • M van de Pas
  • H Fennema
  • T Heijman
  • A Hogewoning
  • A van Leeuwen
  • M van Rooijen
  • F Neienhuijsen
  • M Pelgrim
چکیده

Background Observational postmarketing studies are important to assess vaccine effectiveness (VE). We estimated VE from the bivalent human papillomavirus (HPV) vaccine against HPV positivity of vaccine and nonvaccine types in a high-risk population. Methods We included all vaccine-eligible women from the PASSYON study, a biennial cross-sectional survey in Dutch sexually transmitted infection clinics. Vaginal swabs were analyzed using a polymerase chain reaction-based assay (SPF10-LiPA25) able to detect the 12 high-risk HPV (hrHPV) types 16/18/31/33/35/39/45/51/52/56/58/59. We compared hrHPV positivity between self-reported vaccinated (≥1 dose) and unvaccinated women, and estimated VE by a logistic mixed model. Results We included 1087 women of which 53% were hrHPV positive and 60% reported to be vaccinated. The adjusted pooled VE against HPV-16/18 was 89.9% (81.7%-94.4%). Moreover, we calculated significant VE against nonvaccine types HPV-45 (91%), HPV-35 (57%), HPV-31 (50%), and HPV-52 (37%). Among women who were offered vaccination 5/6 years ago, we estimated similar VE against HPV-16/18 (92%) and all hrHPV types (35%) compared to women who were offered vaccination <5 years ago (83% and 33%, respectively). Conclusion We demonstrated high VE of the bivalent vaccine against HPV-16/18 and cross-protection against HPV-45/35/31/52. Protection against HPV-16/18 was sustained up to 6 years postvaccination.

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Human papillomavirus vaccines and the potential for cross-protection between related HPV types.

The majority of human papillomavirus (HPV) belong to the genus alpha-papillomavirus, which can be further subdivided into species and then strains. Approximately 200 strains of HPV have been identified, and the whole genomes of approximately 100 strains have been (discovered) and completely sequenced. Between 13 and 18 HPV strains have been characterized as conferring a high oncogenic risk, wit...

متن کامل

A review of cross-protection against oncogenic HPV by an HPV-16/18 AS04-adjuvanted cervical cancer vaccine: importance of virological and clinical endpoints and implications for mass vaccination in cervical cancer prevention.

Human papilloma virus (HPV)-16 and -18 are responsible for approximately 70% of invasive cervical cancers worldwide. Other oncogenic HPV types account for almost all the remainder. Importantly, HPV-45 and -31 account for approximately 10%. HPV-18 and -45, along with HPV-16, are found in over 90% of endocervical adenocarcinomas. HPV-45 is the third most frequent HPV type in cervical carcinoma an...

متن کامل

Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model

OBJECTIVES To compare the effect and cost effectiveness of bivalent and quadrivalent human papillomavirus (HPV) vaccination, taking into account differences in licensure indications, protection against non-vaccine type disease, protection against disease related to HPV types 6 and 11, and reported long term immunogenicity. DESIGN A model of HPV transmission and disease previously used to info...

متن کامل

Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands

BACKGROUND Infection with HPV 16 and 18, the major causative agents of cervical cancer, can be prevented through vaccination with a bivalent or quadrivalent vaccine. Both vaccines provide cross-protection against HPV-types not included in the vaccines. In particular, the bivalent vaccine provides additional protection against HPV 31, 33, and 45 and the quadrivalent vaccine against HPV31. The qu...

متن کامل

Impact of vaccine protection against multiple HPV types on the cost-effectiveness of cervical screening.

Cross-protection against non-HPV16/18 types and the emergence of broad spectrum vaccines protecting against multiple HPV types will influence the cost-effectiveness of future screening. To assess this influence we used an individual-based simulation model describing the relation between 14 HPV types and cervical disease, allowing the occurrence of multiple type infections. Screening scenarios f...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره 217  شماره 

صفحات  -

تاریخ انتشار 2018